MaxCyte (MXCT) Earnings Call Presentation

Company Overview - MaxCyte supports 19 clinical and commercial therapies and has 29 SPL customers[9] - The company reported $386 million in 2024 revenue with an 84% Non-GAAP adjusted gross margin[10] - MaxCyte has $190 million in cash and cash equivalents as of December 31, 2024[10] Cell and Gene Therapy Market - There are approximately 1,950 active clinical trials focused on cell and gene therapy as of December 2024[14] - The cell and gene therapy field raised an aggregate of $152 billion in 2024[14] - There are 44 approved cell and gene therapies[14] Strategic Platform Licenses (SPLs) - MaxCyte has 29 SPL customers, with 18 programs currently in clinical development and 1 commercial program[47] - These 18 active clinical programs represent over $220 million of pre-commercial milestone potential[47] - SPL Program-Related revenue accounted for 57% of Core revenue[68] Financial Performance - Total core revenue for the full year 2024 was $325 million, a 9% increase year-over-year[69] - Total revenue for the full year 2024 was $386 million, a 6% decrease year-over-year[69] - Non-GAAP adjusted gross margin was 84% for the full year 2024[69]